


PATENT CLAIMS

1. Use of glucocorticoid receptor antagonists with a relative binding affinity for the glucocorticoid receptor bond between 85% and 155% of that of dexamethasone and with a relative binding affinity for the progesterone receptor bond between 1% and 11% of that of progesterone or with a 14-fold to 150-fold dissociation between the two receptor types, for the production of a drug for the prophylaxis and therapy of glucocorticoid-mediated hypogonadism, sexual dysfunctions and/or infertility.
2. 11 β -Substituted steroids as glucocorticoid receptor antagonists of general formula (I)



wherein

- R₁ is a methyl, methoxy or ethoxy group and
 R₂ is a tert.butyl group, sec.propyl alcohol or sec. propyl ether or a substituted benzene ring.

3. 11 β -Substituted steroids according to Claim 2,
 namely
 21-tert.butyl-17-hydroxy-11 β -(3-methoxyphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
 methyl-4-{17-hydroxy-11 β -[3-(methoxy)phenyl]-3-keto-19-nor-17 α -pregna-4,9-dien-20-yn-21-yl}
 benzoate,
 3-{17-hydroxy-11 β -[3-(methoxy)phenyl]-3-keto-19-nor-17 α -pregna-4,9-dien-20-yn-21-
 yl}}benzaldehyde,
 4-{17-hydroxy-11 β -[3-(methoxy)phenyl]-3-keto-19-nor-17 α -pregna-4,9-dien-20-yn-21-yl}

phenylacetate,
 17-hydroxy-11 β -[3-(methoxy)phenyl]-21-(4-pyrrolyl)phenyl-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
 17-hydroxy-21-(4-hydroxyphenyl)-11 β -[3-(methoxy)phenyl]-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
 17-hydroxy-21-(4-mesylphenyl)-11 β -(3-methoxyphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
 21-tert.butyl-17-hydroxy-11 β -(3-ethoxyphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
 21-(4-tert.butylphenyl)-17-hydroxy-11 β -(3-methoxyphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
 ethyl(E)-3-[17-hydroxy-11 β -(3-methoxyphenyl)-3-keto-19-nor-17 α -pregna-4,9-dien-20-yn-21-yl]} isocrotonate,
 21-(3,5-difluorophenyl)-17-hydroxy-11 β -(3-methoxyphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
 21-(2-trifluorophenyl)-17-hydroxy-11 β -(3-methoxyphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
 21-(3,5-dimethylphenyl)-17-hydroxy-11 β -(3-methoxyphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
 4-{17-hydroxy-11 β -[3-(methoxy)phenyl]-3-keto-19-nor-17 α -pregna-4,9-dien-20-yn-21-yl)} phenylsulfamate,
 17-hydroxy-21-(1-hydroxy-1-methylethyl)-11 β -(3-methoxyphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
 3-(17-hydroxy-3-keto-19-nor-17 α -pregna-4,9-dien-20-yn-11 β -yl)benzaldehyde,
 (E)-3-[17-hydroxy-11 β -(3-methoxyphenyl)-3-keto-19-nor-17 α -pregna-4,9-dien-20-yn-21-yl)benzaldoxime,
 17-hydroxy-21-(1-methoxy-1-methylethyl)-11 β -(3-methoxyphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
 17-hydroxy-21-(4-mesylphenyl)-11 β -(3-methylphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
 17-hydroxy-21-(4-mesyloxyphenyl)-11 β -(3-methylphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one, and
 4-{17-hydroxy-11 β -[3-methylphenyl]-3-keto-19-nor-17 α -pregna-4,9-dien-20-yn-21-yl} phenylaminoacetate.

4. Use of 11 β -substituted steroids as glucocorticoid receptor antagonists according to Claims 2 and 3 for producing a drug for the prophylaxis and therapy of glucocorticoid-mediated hypogonadism, sexual dysfunctions and/or infertility.

5. Use of glucocorticoid receptor antagonists according to Claims 1 to 4, characterized in that

the administration occurs orally, subcutaneously, sublingually, in the form of an inhalator or as a plaster, ointment or gel.

6. Use of glucocorticoid receptor antagonists according to Claims 1 to 5 for producing a drug, characterized in that the daily dose to be administered is from 0.01 mg to 100 mg per body weight [sic].